| Products/Services Used | Details | Operation |
|---|---|---|
| Gene Synthesis | To determine the absolute number of ZIKV copies in each mosquito body or body part, a control plasmid, containing a cloned copy of the targeted ZIKV gene fragment (nucleotides 835 to 911, Genbank accession number EU545988), was constructed. Viral RNA was extracted using the QIAamp Viral RNA Mini Kit (Qiagen, Germany), and cDNA synthesized using the SuperScript III Reverse Transcriptase kit (Invitrogen, Thermo Fisher Scientific, USA) according to the manufacturer’s protocol. The targeted ZIKV fragment was amplified using CloneAmp HiFi PCR Premix (Takara, Clontech Laboratories, USA), and cloned into the pUC19 plasmid vector (Genscript, New Jersey, United States) using the In-Fusion Cloning Kit (Takara, Clontech Laboratories, USA) as described by the manufacturer. | Get A Quote |
BACKGROUND: Recent epidemics of Zika virus (ZIKV) in the Pacific and the Americas have highlighted its potential as an emerging pathogen of global importance. Both Aedes (Ae.) aegypti and Ae. albopictus are known to transmit ZIKV but variable vector competence has been observed between mosquito populations from different geographical regions and different virus strains. Since Australia remains at risk of ZIKV introduction, we evaluated the vector competence of local Ae. aegypti and Ae. albopictus for a Brazilian epidemic ZIKV strain. In addition, we evaluated the impact of daily temperature fluctuations around a mean of 28°C on ZIKV transmission and extrinsic incubation period. METHODOLOGY/PRINCIPAL FINDIN... More
